Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,78 MB, PDF-dokument

Objectives: Pseudomonas aeruginosa colonizes the cystic fibrosis (CF) airways causing chronic bacterial lung infections. CF patients are routinely treated with macrolides, however, P. aeruginosa is considered insusceptible as consequence of inadequate susceptibility testing leaving resistance mechanism completely overlooked. Here, we investigated a new mechanism of macrolide resistance caused by ribosomal protein mutations. Methods: Investigating a longitudinal collection of 529 isolates from CF patients and analysing 5758 protein sequences from different sources, mutations in P. aeruginosa's ribosomal proteins connected to macrolide resistance were identified. Using a modified susceptibility testing protocol, isolates harbouring a mutated uL4 ribosomal protein were tested for resistance against macrolide antibiotics and macrolide-induced quorum sensing modulation. Proteome and ribosome profiling were applied to assess the impact of the mutations on the bacterial physiology. Results: Five uL4 mutations were identified in isolates from different CF patients. Most mapped to the conserved loop region of uL4 and resulted in increased macrolide tolerance (>10-fold relative to wt strains). Greater concentrations (>10-fold) of macrolide antibiotic were needed to inhibit the growth, reduce swimming motility, and induce redox sensitivity of the uL4 mutants. 16 proteins involved in ribosome adaptation displayed altered expression possibly to compensate for the uL4 mutations, which changed the ribosome stoichiometry without negatively affecting bacterial physiology. Conclusions: Macrolide antibiotics should, therefore, be considered as active antimicrobial agents against P. aeruginosa and resistance development should be contemplated when patients are treated with prolonged courses of macrolides. Importantly, improved macrolide susceptibility testing is necessary for the detection of resistant bacteria.

OriginalsprogEngelsk
TidsskriftClinical Microbiology and Infection
Vol/bind28
Udgave nummer12
Sider (fra-til)1594-1601
ISSN1198-743X
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This research was funded by the “Cystic Fibrosis Foundation” (CFF), grant number MOLIN18G0, the “Cystic Fibrosis Trust”, Strategic Research Centre Award—2019— SRC 017, by “The Novo Nordisk Foundation Center for Biosustainability (CfB)” grant NNF10CC1016517 and NNF20CC0035580, and by the “Independent Research Fund Denmark/Natural Sciences” grant 9040-00106B. H.K.J. was supported by the “ Novo Nordisk Foundation” grant NNF12OC1015920, NNF18OC0052776 and NNF19OC0056411, and by the “Independent Research Fund Denmark/Medical and Health Sciences” grant DFF-9039-00037A.

Publisher Copyright:
© 2022 The Author(s)

ID: 322116665